Parsons C Lowell
Division of Urology, University of California, San Diego, Medical Center, San Diego, California 92103-8897, USA.
Urology. 2005 Jan;65(1):45-8. doi: 10.1016/j.urology.2004.08.056.
To test the efficacy of a new intravesical therapeutic solution in relieving urgency/frequency and pain in interstitial cystitis (IC).
A solution of 40,000 U heparin, 8 mL 1% lidocaine (80 mg; group 1) or 2% lidocaine (160 mg; group 2), and 3 mL 8.4% sodium bicarbonate was administered intravesically in patients with newly diagnosed IC with significant frequency, urgency, and pain. Using the Patient Overall Rating of Improvement of Symptoms, the response to treatment was evaluated within 20 minutes of instillation in all patients, after 24 to 48 hours in group 2, and after three treatments per week for 2 weeks in group 2 patients who elected to receive additional instillations. Significant symptom relief was defined as 50% or greater symptom improvement.
After one instillation, 35 (75%) of 47 patients in group 1 (1% lidocaine) and 33 (94%) of 35 in group 2 (2% lidocaine) reported significant immediate symptom relief. The difference in the response rates was statistically significant (P <0.01). In group 2, 50% of the subjects experienced at least 4 hours of symptom relief from the single instillation, and 16 (80%) of 20 reported significant sustained symptom relief after 2 weeks of treatment.
Intravesical treatment with combined heparin and alkalinized lidocaine immediately reduced the pain and urgency of IC in most patients treated for newly diagnosed IC. Symptom relief lasted beyond the duration of the local anesthetic activity of lidocaine, suggesting the solution suppresses neurologic upregulation. In IC treatment, this new intravesical solution may be helpful in the interval before heparinoid therapy reaches its full effect.
测试一种新型膀胱内治疗溶液缓解间质性膀胱炎(IC)患者尿急/尿频及疼痛的疗效。
将40000单位肝素、8毫升1%利多卡因(80毫克;第1组)或2%利多卡因(160毫克;第2组)以及3毫升8.4%碳酸氢钠的溶液膀胱内注入新诊断为IC且有明显尿频、尿急和疼痛的患者体内。使用患者症状总体改善评分,在所有患者注入后20分钟内、第2组在24至48小时后以及第2组中选择接受额外注入的患者每周进行3次治疗,持续2周后评估治疗反应。显著的症状缓解定义为症状改善50%或更多。
注入一次后,第1组(1%利多卡因)的47例患者中有35例(75%)、第2组(2%利多卡因)的35例中有33例(94%)报告症状立即得到显著缓解。反应率差异具有统计学意义(P<0.01)。在第2组中,50%的受试者单次注入后症状缓解至少持续4小时,20例中有16例(80%)在治疗2周后报告症状持续显著缓解。
肝素与碱化利多卡因联合膀胱内治疗可立即减轻大多数新诊断为IC的患者的疼痛和尿急。症状缓解持续时间超过利多卡因局部麻醉作用的持续时间,提示该溶液可抑制神经上调。在IC治疗中,这种新型膀胱内溶液可能在类肝素疗法达到充分效果之前的间隔期有所帮助。